Synlett, Год журнала: 2025, Номер unknown

Опубликована: Март 6, 2025

Abstract The paradigm of cancer treatment has been shifting from traditional approaches to metal-based therapies; however, achieving effective and targeted treatments remains a significant challenge. journey drugs began with the serendipitous discovery cisplatin, which paved way for development various platinum derivatives. Additionally, other metals, such as ruthenium (Ru), nickel (Ni), zinc (Zn), copper (Cu), have explored their therapeutic potential. Among these, ruthenium-based complexes stand out due unique redox properties, high selectivity, remarkable chelation capabilities, making them promising candidates therapy. This Account aims provide comprehensive overview metal complexes, current status, pharmacological chemical classification. These pharmacophores enable selective delivery cytotoxic payloads cells while sparing healthy cells. Notably, complex IT-139 (formerly NKP-1339) demonstrated promise in clinical studies types, exhibiting lower toxicity than platinum-based therapies. also highlights advances. It readers detailed understanding role drug development, its mechanisms action, potential applications personalized treatments. exploration underscores both without active molecules, emerge safe oncology. 1 Introduction 2 Importance Ruthenium Metal Complexes 3 Synthesis 4 Classification Complex Antitumor Drugs Based on Mode Action 5 Structure Oxidation State 6 Current Status Drug Clinical Trials 7 Applications Metals Other 8 Conclusion

Язык: Английский